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Large amounts of free granulocyte elastase (GE), an enzyme capable of mediating airway
damage, have been found in bronchial secretions of patients with cystic fibrosis who are
infected with Pseudomonas aeruginosa. This finding indicates an imbalance between GE
and its antiproteases, acproteinase inhibitor (ai-PI) and bronchial mucosal inhibitor (BMI),
in the airways of these individuals. The effect of intravenous antimicrobial treatment against
P. aeruginosa on activity and concentration of GE, BMI, and ai-PI was evaluated in 30
treatment courses of 20 patients with cystic fibrosis. Although sputum volume and level
of immunoreactive GE decreased and concentrations of ai-PI and BMI increased signifi-
cantly (P < .05), a high level of free GE persisted. No active ai-PI and BMI were detect-
able after treatment. High levels of GE correlated with a poor pulmonary condition
(rs = .98, P < .001). In vitro, elastolytic activity of bronchial secretions from patients
with cystic fibrosis was significantly inhibited by eglin C and an oxidation-resistant vari-
ant of ai-PI, both compounds currently produced by recombinant DNA technology.
Individuals with cystic fibrosis suffer from a chronic
infection of the airways characterized by progressive
destruction of small bronchioles and later of large
airways [1-3]. In these patients, colonization of the
bronchial tree with Pseudomonas aeruginosa is
related to the severity of the lung disease, as shown
by deterioration of the clinical condition, radio-
graphic findings, and lung function tests [2,4]. The
mechanisms involved in bronchial and bronchiolar
damage are not precisely known. However, evidence
is accumulating that the local inflammatory reac-
tion and immune response may be involved in tissue
damage [3, 5,6]. We have recently demonstrated that
bronchial secretions from individuals with cystic
fibrosis who are infected with R aeruginosa con-
tained large amounts of elastolytic activity attributa-
ble to granulocyte elastase (GE) [7]. GE is a potent
proteolytic enzyme present in the primary granules
of granulocytes [8]; it has proteolytic activity on
structural proteins of the lung, such as elastin, col-
lagen, and proteoglycan [9, 10]. We further showed
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that R aeruginosa isolated from this group of pa-
tients with cystic fibrosis secreted in vitro bacterial
elastase, an enzyme capable of inactivating ac
proteinase inhibitor (ai-PI) [11] and bronchial
mucosal inhibitor (BMI) [12], which are the two main
inhibitors protecting the lower and upper respiratory
tract from the activity of GE [9, 13]. The large
amounts of free GE found in bronchial secretions
from these subjects with cystic fibrosis could have
resulted from an increased number of granulocytes
(and, therefore, GE in the bronchial tree of these pa-
tients), a decreased local inhibitor potential for GE,
or a combination of these two mechanisms.
In this study we evaluated the effect of iv an-
timicrobial therapy against Pseudomonas on activ-
ity and concentration of GE as well as on inhibitor
activities and volumes of bronchial secretions of pa-
tients with cystic fibrosis who were infected with
R aeruginosa. Some individuals were followed up for
three years. We also determined in vitro the effect
of various inhibitors of GE [14-16] on the elasto-
lytic activity of bronchial secretions from the sub-
jects we studied.
Subjects and Methods
Twenty patients with cystic fibrosis were prospec-
tively included in the study. The diagnosis of cystic
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fibrosis had been established on clinical features of
the disease and was confirmed by sweat concentra-
tions of Na" and CI- of >70 mEq/liter. All patients
were studied while they were hospitalized at Chil-
dren's Hospital (University of Bern, Bern, Switzer-
land) for iv antimicrobial therapy. Their mean ± SD
age was 16.5 ± 5 years. They all had cultures of spu-
tum positive for R aeruginosa; two were also posi-
tive for Staphylococcus aureus. In total, 30 treatment
courses were given to these 20 patients. The dura-
tion of therapy was 10-17days (mean, 14days). Netil-
micin (11 mg/kg per day) and in addition either
azlocillin (500 mg/kg per day) or ticarcillin (500
mg/kg per day) were given for 14 days. Flucloxacil-
lin was added for the patients infected with S. aureus
at 150 mg/kg per day.
The following clinical and laboratory parameters
were determined before initiation and at the end of
antimicrobial therapy. All patients had a complete
white blood cell count. Clinical and radiographic
staging of cystic fibrosis was performed by one of
us, unaware of the laboratory results, with use of a
scoring system outlined previously [17]. This clini-
cal/radiographic scoring system included five param-
eters: physical activity, general physical condition and
bacteriology of sputum, signs of pulmonary disease,
radiological lung involvement, and gastrointestinal
manifestations. Each parameter was rated on the ba-
sis of 1-5 points, with the highest score indicating
the best status; thus the maximum clinical/radio-
graphic score indicated the best status. The maxi-
mum score obtainable was therefore 25. Severity of
disease was graded into five stages (I-V). Radio-
graphic scoring was performed with the scoring sys-
tem of Chrispin and Norman [18]. The highest stage
(V) corresponds to poor clinical condition and ad-
vanced radiographic alterations typical for cystic
fibrosis.
Preparation ofsputum samples. For the present
study, sputum samples were analyzed as follows.
Semiquantitative leukocyte counts were determined
with standard methods [19] by using scores ranging
from 1 to 4. A score of 4 means >25 leukocytes per
high-power field (magnification, 10) in each of five
high-power fields examined; a score of 3 means 15-25
leukocytes under the same conditions. Sputum was
inoculated onto blood, chocolate, and McConkey's
agars, and identification of the pathogens was done
with standard methods [20]. Fresh morning sputum
obtained after chest physiotherapy was immediately
mixed with an identical volume of sterile 0.9070 NaCI
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and centrifuged at 1,000 g until the supernatant was
clear. The supernatants were stored at -70 C until
tested. Their protein concentration was determined
with a standard method (Biorad, Richmond, Calif).
In 15 patients the 24-hr sputum volume was mea-
sured before and after treatment.
Activities and concentration ofGE. The elasto-
lytic activity was measured according to the proce-
dure of Hornebeck and Schnebli [21] with purified
bovine elastin (Sigma, St. Louis) radiolabeled with
3H (New England Nuclear Corp., Boston). Ten
microliters of the test sample was incubated with 500
IJgof [3H]-elastin suspended in 0.1 MTris buffer (pH
8.2) containing 0.01070 23 lauryl ether (Brij® 35;
Sigma) and 0.02070 sodium azide for 16 hr at 37 C.
The samples were then centrifuged at 3,300 g for 10
min. The radioactivity of 100 IJI of the supernatant
was measured and used to calculate the amount of
solubilized elastin. One milligram of completely
solubilized elastin corresponded to 145,000 cpm.
Elastolytic activity (in UE) was expressed as milli-
grams of labeled elastin solubilized by 1 ml of un-
diluted bronchial secretions.
GE-like activity was measured with use of the GE-
specific substrate Suc-Ala-Ala-Pro-Val-7-amino-4-
methylcoumarin (Calbiochem-Behring, Lucerne,
Switzerland). The sequence Ala-Ala-Pro-Val has
been shown to be specific for GE [22]. Because the
specificity of a small peptide substrate like the one
that we used for a specific enzyme cannot be proven
when working with biologic fluids, we chose the term
GE-like. GE-like activity was expressed in UG (jmrol
of 7-amino-4-methylcoumarin liberated/min by 1 ml
of enzyme solution at 30 C [extinction coefficient,
12,300 at 360 nm]). The determinations were per-
formed in a spectrophotometer (Beckman, Palo
Alto, Calif) with thermostatted cuvettes and a con-
tinuous recording table.
Both enzymatic reactions measured were linear
over the recording time.
The concentration of GE was determined in 30
paired samples with use of an RIA [23].
The elastolytic activity of 10 IJg of purified GE
was 0.6 UE, and the GE-like activity was 0.055 UG
(means of triplicate determinations).
Purified human GE [24], a gift from Dr. H. P.
Schnebli (Ciba-Geigy, Basel, Switzerland) was used
as the standard. The elastolytic and GE-like activi-
ties of this amount of purified GE were inhibited
by 98070 and 100070, respectively, when 2 mM phe-
nylmethylsulfonyl fluoride was used as inhibitor.
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Concentrations and activities ofinhibitors. Con-
centrations of ai-PI and a2-macroglobulin (a2-M)
were measured in 30 paired samples by radial im-
munodiffusion with use of Partigen'" LC plates
(Behringwerke, Marburg, Federal Republic of Ger-
many). Samples were diluted appropriately, and con-
centrations were calculated from the linear regression
coefficient with use of standards at five concentrations.
The concentration of BMI was measured as pre-
viously described [25].
To determine whether free active ai-PI or BMI was
present in the bronchial secretions, we performed the
following experiments. Crossed immunoelectropho-
resis for a.-PI was done with a standard technique
[26] with human serum as a control. The agarose
gel (Seakem'"; batch 50013; Marine Colloids, Rock-
land, Me) contained antiserum to a.-PI (Laboratory
of the Department of Surgical Pathophysiology,
Malmo General Hospital, Malmo, Sweden) [27]. Pre-
and posttreatment samples of bronchial secretions
were analyzed in the absence or presence of trypsin
(Sigma) at six times the molar concentration of a.-PI.
In addition, 10 pre- and posttreatment bronchial
secretions were pooled, and gel filtration was per-
formed on a 1.6- x 100-cm column of Sephadex"
G-50 (Pharmacia Fine Chemicals, Uppsala, Swe-
den). The column was equilibrated with 0.05 MTris-
HCI buffer (pH 7.4) containing 1.0 M NaCI and
0.005 MEDTA. Pooled bronchial secretions (1.3 ml)
were loaded on the column. The flow rate was 20
ml/hr with a fraction volume of 4 ml/hr. The frac-
tions were analyzed for BMI, GE [23], and GE-like
activity [22].
Inhibition experiments. The inhibitory effect of
four inhibitors of GE on elastolytic and GE-like ac-
tivity was measured: an oxidation-resistant variant
of ai-PI [16] (the gift of Dr. Michael Courtney, Trans-
gene SA, Strasbourg, France), partially purified al-
PI (Sigma), phenylmethylsulfonyl fluoride (Sigma),
and eglin C, a small polypeptide inhibitor specific
for GE [15] (the gift from Dr. U. Seemiiller, Insti-
tute for Clinical Chemistry, Munich). On each
sample the inhibitory activity of o-phenantroline
(Merck, Darmstadt, Federal Republic of Germany),
an inhibitor of pseudomonas elastase [28], was also
determined. The inhibitors and the enzyme solution
were allowed to react for 1 min before the substrate
was added. Inhibition was determined from the ex-
pression 100 - ([enzymatic activity of the sample
with the inhibitor/enzymatic activity of the sample
without the inhibitor] x 100).
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Statistical analysis. Data are expressed as mean
± SD values. For comparisons of results before and
after treatment, the Wilcoxon rank test was used.
Correlations were calculated with use of Spearman's
correlation coefficient, when scores were compared
with laboratory results.
Results
Clinical and radiographic scores, white blood cell
counts, and sputum leukocyte scores. Antimicro-
bial treatment resulted in significant improvement
of clinical condition and radiographic findings, as
determined by our scoring system. In 18 of the 30
treatment courses analyzed, treatment resulted in a
decrease of one disease stage, and no change was ob-
served in 12 treatment courses (P < .001).
The mean white blood cell count decreased sig-
nificantly from 13,524 ± 4,585/I.tI before to 7,367
± 2,897//AI after treatment (P < .001). Despite a
statistically significant decrease in the mean sputum
leukocyte score (P< .001)from a mean of 3.9 (range,
3-4) to 3.5 (range, 2-4) after treatment, none of the
patients had a score of <2 after treatment.
Cultures of sputum. Cultures of sputum for
P. aeruginosa were negative at the end of treatment
in 12of 30 treatment courses. However, the cultures
were positive for P. aeruginosa in all patients within
one month after treatment.
The total sputum volume, in ml/24 hr, decreased
by 25010-90010 at the end of treatment (mean, 60010;
P < .001).
Concentration and activities ofelastase, concen-
trations and activities of inhibitors, and concentra-
tions oftotal protein in sputum. Table 1 shows the
results of sputum analysis before and after an-
timicrobial therapy. Of the levels of immunoreac-
tive GE, elastolytic activity, and GE-like activity, only
the decrease in level of immunoreactive GE was
statistically significant (P < .05) in a comparison of
sample pairs.
In all sputum samples tested in this study, elasto-
lytic activity was inhibited by >85010 with 2 mM
phenylmethylsulfonyl fluoride, an inhibitor of ser-
ine proteases such as GE, but not by 10 roM o-phe-
nantroline, an inhibitor of P. aeruginosa elastase [28].
This observation confirms that elastolytic activity
in these sputum samples did not derive from P. aeru-
ginosa elastase or macrophage elastase [29], the third
elastase possibly involved in elastolytic activity.
Table 1 also shows the concentrations of the in-
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Table 1. Results of sputum analysis before and after antimicrobial therapy.
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Antimicrobial therapy No. of
Parameter Before After pairs tested p*
Enzymatic activity
Elastolytic activity (UE) 2.1 ± 1.1 2.4 ± 1.7 30 NS
GE-like activity (UG) 0.64 ± 0.62 0.75 ± 0.62 30 NS
GE (J,lg/ml) 89.7 ± 52.4 63.7 ± 32.0 15 <.05
Inhibitor concentration
ai-PI (mg/g of protein) 6.3 ± 6.0 11.4 ± 7.1 15 <.05
a2-M (mg/g of protein) 7.4 ± 5.6 6.9 ± 5.5 15 NS
BMI (ng/mg of protein) 223 ± 204 927 ± 2,231 15 .05
Total protein concentration
(g/liter) 10.3 ± 6.2 9.1 ± 5.3 30 NS
NOTE. Data are mean ± SD values. NS = not significant.
* By Wilcoxon rank test.
hibitors acPI, a2-M, and BMI in sputum before and
after therapy. The differences in levels of acPI and
BMI were statistically significant (P < .05 and P
= .05, respectively).
The difference in the concentration of total pro-
tein in sputum before and after therapy was not sig-
nificant (table 1).
When levels of free GE determined as elastolytic
activity inhibited by 2 mM phenylmethylsulfonyl
Table 2. Levels of free elastase and immunoreactive GE
in cystic fibrotic sputum samples before and after
antimicrobial therapy.
Free Immunoreactive
elastase (ug/ml) GE (J,lg/ml)
Subject no. Before After Before After
1 20 20 60 48
2 47 28 84 104
3 38 36 200 52
4 36 43 96 66
5 19 6 28 9
6 18 132 47 124
7 35 28 60 42
8 16 64 76 124
9 62 28 90 60
10 66 45 94 74
11 87 71 200 108
12 40 21 74 50
13 16 6 19 62
14 30 8 76 11
NOTE. The level of free elastase was determined by meas-
urement of elastolytic activity with purified GE as the standard.
The elastolytic activity was inhibited by 89070-98070 by 2 mM
phenylmethylsulfonyl fluoride, which characterizes it as a ser-
ine protease such as GE. The level of immunoreactive GE was
determined as described by Ohlsson and Olsson [23].
fluoride were expressed as ug of GE, the concentra-
tion of immunoreactive GE always exceeded the lev-
els of free elastase except in one sample (table 2).
In the other 29 samples, free elastase represented
from 13070 to 84070 of the immunoreactive GE. On
crossed immunoelectrophoresis, at-PI was shown to
migrate in two peaks (figure 1) within the bronchial
secretions. The migration pattern of at-PI in human
serum is shown for comparison (figure 1, top). The
first peak corresponds to at-PI not bound to elastase,
but it migrates slightly differently than unaltered at-
PI. The second, smaller peak corresponds to at-PI
complexed with elastase (figure 1, middle). When the
cystic fibrotic bronchial secretion was allowed to re-
act with an excess of trypsin, no trypsin-reactive er.-
PI was found (figure 1, bottom), a result suggesting
that all of the immunoreactive at-PI was present in
an inactive form.
Also, the gel filtration of 13 pooled samples of
sputum showed that most of the BMI was found in
the fraction corresponding to the complex between
BMI and GE. Free elastase was found in the corre-
sponding fraction (data not shown), but no free BMI
could be demonstrated.
Inhibition ofelastolytic activity ofcystic fibrotic
sputum by the oxidation-resistant variant ofarPI,
partially purified aI-PI, and eglin C in vitro. The
calculated elastase content of 10 iiI of cystic fibrotic
sputum varied from 0.06 to 1.32lig of GE. The mean
inhibition of the elastolytic activity of 10iiIof cystic
fibrotic sputum was 73070 (range, 46070-95070) in the
presence of 5 lig of the oxidation-resistant variant
of at-PI (n = 10) and 89070 (range, 61070-100070) with
50 1Jg of partially purified at-PI (n = 27). The 50
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Figure 1. An example of the migration pattern of Cl',-PI
in 100 1-11 of a cysticfibrotic bronchial secretionon crossed
immunoelectrophoresis. The cathode is at the left, and the
anode is at the right. The agarose gel, which contained
antiserum to Cl',-PI, shows the migration pattern of (top,
a) a,-PI in human serum, (middle, b) aI-PI in an untreated
bronchial secretion, and (bottom, c) ai-PI in a bronchial
secretion in the presence of trypsin at six times the molar
concentration of a,-PI. There is a smaIlpeak at the right,
whichcorresponds to Cl', -PI bound to enzyme, and a larger
peak at the left, which migrates slightly differently from
a,-PI in serum. The presence of ai-PI that does not react
with trypsin and migratesdifferently from enzyme-bound
a,-PI indicates that this peak corresponds to inactive, un-
bound a, -PI. This trypsin-unreactive a,-PI also migrates
slightly differently from aI-PI in human serum.
J-Ig of this preparation of at-PI corresponded to rv5
J-Ig of completely purified aI-PI. When 10J-Ig of eglin
C was used to inhibit the elastolytic activity of 10
J-Il of cystic fibrotic sputum (n = 27) it resulted in
a mean inhibition of 35070 (range, 0070-64070), whereas
100 J-Ig of eglin C (n = 9) resulted in a mean inhibi-
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tion of 74070 (range, 58070-95070). In comparison, the
elastolytic activity of 1.57 J-Ig of purified GE, which
had an elastolytic activity slightly higher than the
amounts of cystic fibrotic sputum samples tested,
was inhibited by 98070 with 5 J-Ig of the oxidation-
resistant mutant of at-PI and with 50 J-Ig of partially
purified ai-PI, by 83070 with 10 J-Ig of eglin C, and by
95070 with 100J-Ig of eglin C. These results show that
the amount of inhibitor required for inhibition of
elastolytic activity of cystic fibrotic sputum samples
is higher than the amount needed to inhibit the
elastolytic activity of purified GE.
Correlations of clinical and radiographic scores
and the age of the patients with elastolytic activity
of sputum samples. A highly significant correla-
tion was found when elastolytic activity of sputum
samples before and after treatment was compared
with disease stages. High elastolytic activity of spu-
tum samples correlated with high disease stages (rs
= .98, P < .001).
Discussion
In this group of patients with cystic fibrosis who were
infected with P. aeruginosa, the clinical and pulmo-
nary condition, as determined by a five-stage scor-
ing system, improved significantly after antimicrobial
treatment. The level of total immunoreactive GE,
which represents free and inhibitor-bound GE, de-
creased significantly, and levels of immunoreactive
a,-PI and the BMI, the main inhibitors of GE in the
respiratory tract, increased (table I). Despite this de-
crease in the total GE content, which was important
because sputum volume had also decreased signifi-
cantly, free elastolytic activity per milliliter of spu-
tum remained elevated. We calculated that the mean
concentration of GE in this group of patients was
55 J-Ig/ml of sputum, which corresponds to the
elastase content of 1.5 X 107 granulocytes [8]. Thus
the airways of these patients were continuously ex-
posed to free GE. In addition, we always observed
a gradual increase in sputum volume during the
treatment-free intervals in those patients followed up
prospectively for three years. These findings are
clearly different from what was observed in adults
with chronic bronchitis and bronchiectases, in whom
elastolytic activity of sputum was significantly lower
than in patients with cystic fibrosis [7]. Also, in adults
with chronic bronchitis, antimicrobial therapy for
acute exacerbation was found to lead to a decrease
in elastolytic activity [30].
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Until now, most studies reporting free elastolytic
activity in sputum were restricted to patients with
cystic fibrosis who were infected with R aeruginosa
[7, 31-33], and the patients were not followed up
prospectively for longer periods. In several studies
[7, 32, 33] elastolytic activity in cystic fibrotic spu-
tum was shown to derive mainly from GE and not
from R aeruginosa elastase, with the exception of
one report [31] in which the results from experiments
with inhibitors suggested that R aeruginos elastase
might contribute to the elastolytic activity measured.
In addition to our patients with cystic fibrosis who
were infected with R aeruginosa, we also measured
levels of free GE in the bronchial secretions of six
patients with cystic fibrosis who were not infected
with R aeruginosa. Sputum from five patients
colonized with S. aureus contained levels of free GE
from 10 to 32 ug/rnl. In secretions aspirated from
the left mainstem bronchus of a one-year-old girl
with cystic fibrosis who was infected with Escherichia
coli, we measured a level of 40 ug/ml, and in secre-
tions from the bronchus of the right lower lobe,
which was the main focus of chronic infection in this
child, we found a concentration of 140 J.tg of free
GE/ml. Thus the presence of large amounts of GE
in the airways of these subjects may precede the on-
set of colonization with R aeruginosa. In all indi-
viduals colonized with R aeruginosa, we found that
advanced disease stage correlated with high elasto-
lytic activity of sputum. It is important to note that
this observation does not mean that there is a causal
relationship between these two parameters, but rather
it is a demonstration of a correlation of pronounced
inflammation with advanced disease stages.
What are the possible causes in individuals with
cystic fibrosis for this persistent imbalance between
GE and its main antiproteases? The high levels of
immunoreactive GE (table 2), which always exceeded
those of free elastase except in one sample, clearly
show that excessive numbers of granulocytes were
present in the airways of these patients and that the
amount of released GE may have exceeded the local
inhibitor potential. In addition, oxidants released by
granulocytes during phagocytosis may inactivate the
elastase inhibitory capacity of aI-PI [34]. In the pres-
ent study we also tried to define in vivo the role of
R aeruginosa elastase, which in vitro has proteolytic
activity on a series of proteins involved in inflam-
matory reactions and the immune response [7, 11,
12, 35, 36]. We found no evidence that BMI was in-
activated by R aeruginosa elastase in the sputum of
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our patients with cystic fibrosis because gel filtra-
tion of sputum samples showed that all the BMI was
bound to GE. (Since the submission of this report,
this finding has also been confirmed in another study
[32].) On the basis of our experiments, we conclude
that the aI-PI in cystic fibrotic bronchial secretions
was present in inactive forms only, but we can not
distinguish whether acPI was inactivated by oxidants
[34] or R aeruginosa elastase. On crossed immuno-
electrophoresis, the aI-PI in an untreated bronchial
secretion (figure 1, middle) migrated slightly differ-
ently from the aI-PI in serum (figure 1, top). When
the same bronchial secretion was allowed to react
with trypsin before immunoelectrophoresis (figure
1, bottom), no trypsin-reactive aI-PI was found. A
small amount of enzyme-bound acPI was also de-
tectable.
That the large numbers of granulocytes and the
high levels of free GE are most likely involved in tis-
sue damage in individuals with cystic fibrosis is sug-
gested by several other studies. In a recent report [33]
biochemical and pathological evidence for proteo-
lytic destruction of lung connective tissue in cystic
fibrosis due to elastase was presented. Furthermore,
the tissue-damaging effects of granulocyte proteases
as well as oxidants, which may be released from
granulocytes, were well documented in experimen-
tal models [37], and the substrate spectrum of GE
includes elastin, collagen, and proteoglycan [9, 10],
all three of which are important structural proteins
of the lung. In addition, GE also has proteolytic ac-
tivity on opsonins such as C3 [7] in cystic fibrotic
bronchial secretions as well as on immunoglobulins
in vitro [38, 39]. Fragmentation of IgG into frag-
ments resembling those generated by GE were
demonstrated in bronchial secretions in cystic fibrosis
[33]; however, in a subsequent report, these authors
presented evidence that R aeruginosa elastase in vitro
may also be involved in IgG cleavage [36]. At pres-
ent, cleavage of IgG by R aeruginosa elastase within
the bronchial tree of patients with cystic fibrosis has
not been demonstrated. In other chronic pyogenic
infections such as pleural empyema caused by a va-
riety of bacterial pathogens, proteolysis of C3 was
due to GE [40], and fragmentation of immunoglob-
ulins was also observed [41]. Thus the precise role
that R aeruginosa elastase plays in vivo in individuls
with cystic fibrosis who are infected with this patho-
gen remains to be established.
Taken together, our observations and those of
others suggest that in cystic fibrosis, GE may con-
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tribute to tissue damage as well as microbial persist-
ence by proteolytic degradation of opsonins. Inhi-
bition of GE by synthetic inhibitors of this enzyme
potentially may prevent airway damage. We tested
two inhibitors of GE for their potential to inhibit
elastolytic activity of cystic fibrotic bronchial secre-
tions in vitro. Eglin C, a synthetic GE inhibitor [15],
and an oxidation-resistant mutant of ai-PI [16] both
substantially suppressed elastolytic activity of cys-
tic fibrotic bronchial secretions in vitro. The elasto-
lytic activity of purified GE was inhibited to a greater
extent by both inhibitors than was that of bronchial
secretions, a phenomenon that may be due to bind-
ing of these inhibitors to enzmes or proteins other
than GE. Eglin C was shown to be devoid of toxic-
ity in an experimental animal model [42], and both
compounds are currently produced by recombinant
DNA technology [16, 43] and may in the future be
available for clinical studies.
In summary, the clinical and pulmonary condi-
tion of our patients with cystic fibrosis who were in-
fected with R aeruginosa was significantly improved
by iv antimicrobial therapy against R aeruginosa.
A transient eradication of the organism from spu-
tum was obtained in 12of 30 treatment courses, and
the sputum volume per 24-hr interval decreased tran-
siently. However, in all bronchial secretions studied,
including those of six patients who were not
colonized with R aeruginosa, high levels of free GE
were found. Before as well as after treatment in the
patients infected with R aeruginosa, ai-PI and BMI
were found in inactive forms. These high levels of
free granulocyte neutral proteases in the airways per-
sisted for prolonged periods, and high proteolytic
activity correlated with advanced pulmonary disease.
Because in vitro elastolytic activity of cystic fibrotic
bronchial secretions was due to GE and was substan-
tially inhibited by eglin C and an oxidation-resistant
variant of ai-PI, we suggest that these compounds,
as soon as they have been shown to be devoid of tox-
icity, be evaluated for their potential of preventing
progressive airway damage in individuals with cys-
tic fibrosis, in addition to appropriate antimicrobial
therapy.
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